Alembic Pharmaceuticals Inc., a wholly owned subsidiary of Alembic Pharmaceuticals Ltd., has acquired Utility Therapeutics Ltd. to expand its UTI drug portfolio in the US. The acquisition includes 100% ownership of Utility Therapeutics.The acquisition cost is approximately $12 million, and the deal is expected to be completed within 30 days.
The company aims to commercialise Utility’s FDA-approved and pipeline products in the US market.
There was no related-party or promoter involvement in the transaction, according to a filing made by the company with the stock exchange.Utility Therapeutics specialises in the development and approval of branded pharmaceutical products for the treatment of urinary tract infections (UTIs).
The company aims to commercialise Utility’s FDA-approved and pipeline products in the US market.
There was no related-party or promoter involvement in the transaction, according to a filing made by the company with the stock exchange.Utility Therapeutics specialises in the development and approval of branded pharmaceutical products for the treatment of urinary tract infections (UTIs).
Earlier on June 30, Alembic Pharmaceuticals said that it has received the final approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Doxorubicin Hydrochloride Liposome injection.
The injection is indicated for the treatment of ovarian cancer, AIDS-related Kaposi Sarcoma and multiple myeloma.
Shares of Alembic Pharmaceuticals Ltd. settled 2.08% lower on Wednesday at ₹991. On a year-to-date basis, the stock is down 6%.
First Published: Jul 3, 2025 9:09 AM IS
